11 unknown, 6 recruiting, 2 suspended, 1 not yet recruiting. 14 Phase 1, 5 Early Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Unknown 6, Recruiting 5, Suspended 2, Not yet recruiting 1 |
| Early Phase 1 | 5 | Unknown 5 |
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow iCell Gene Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T following lymphodepletion - Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | Phase 2 | Recruiting | iCell Gene Therapeutics | 20 | 2026-09-01 | 2026-09-17 |
| Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia Anti-CD33-CLL1 CAR-T cells (ICG415) following lymphodepleting fludarabine and cyclophosphamide - Acute Myeloid Leukemia (AML) | Phase 1 | Recruiting | iCell Gene Therapeutics | 18 | 2026-06-10 | 2026-06-25 |
| BCMA-CD19 cCAR T for the Treatment of Refractory Inflammatory Bowel Disease (IBD) ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T - Inflammatory Bowel Diseases (IBD) | Phase 1 / Phase 2 | Not yet recruiting | iCell Gene Therapeutics | 18 | 2026-04-07 | 2026-04-22 |
| BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR-T - Inflammatory Myopathy | Phase 1 | Recruiting | iCell Gene Therapeutics | 10 | 2025-03-20 | 2026-07-20 |
| BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases BCMA-CD19 cCAR T cells - Refractory Immune Cytopenia | Phase 1 | Recruiting | iCell Gene Therapeutics | 20 | 2024-08-31 | 2025-01-22 |
| Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant CD4CAR - Acute Myeloid Leukemia | Phase 1 | Suspended | Huda Salman | 30 | 2024-03-19 | 2026-09-30 |
| Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML. CD4CAR - Chronic Myelomonocytic Leukemia | Phase 1 | Suspended | Huda Salman | 30 | 2024-02-21 | 2026-09-24 |
| CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma CD7CAR T cells - Relapsed/Refractory, High Risk Hematologic Malignancies, T-ALL/Lymphoma | Phase 1 | Unknown | iCell Gene Therapeutics | 24 | 2022-07-01 | 2022-07-06 |
| Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia anti-CD33 CAR T cells - Relapsed and/or Refractory Acute Myeloid Leukemia, High Risk Hematologic Malignancies | Phase 1 | Unknown | iCell Gene Therapeutics | 10 | 2022-07-01 | 2022-07-06 |
| BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE) BCMA-CD19 cCAR T cells - Relapsed/Refractory, Systemic Lupus Erythematosus (SLE) | Phase 1 | Unknown | iCell Gene Therapeutics | 15 | 2022-04-01 | 2022-07-26 |
| Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances CD7 CAR T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma | Phase 1 | Unknown | iCell Gene Therapeutics | 20 | 2020-12-01 | 2021-06-22 |
| Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies anti-CD5 CAR T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Non-Hodgkin Lymphoma | Phase 1 | Unknown | iCell Gene Therapeutics | 20 | 2020-12-01 | 2021-03-02 |
| CD4CAR for CD4+ Leukemia and Lymphoma CD4CAR - T-cell Lymphoma, T-cell Leukemia | Phase 1 | Recruiting | Huda Salman | 20 | 2020-07-09 | 2026-06-24 |
| CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies CD4 CAR T cells - T Cell Lymphoma in Relapse, Refractory T-Cell Lymphoma | Phase 1 | Unknown | iCell Gene Therapeutics | 12 | 2019-07-11 | 2021-05-19 |
| BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma BCMA-CD19 cCAR T cells - Multiple Myeloma in Relapse, Refractory Multiple Myeloma | Phase 1 | Recruiting | iCell Gene Therapeutics | 12 | 2019-07-01 | 2025-09-16 |
| BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma BCMA-CS1 cCAR T cells - Multiple Myeloma | Early Phase 1 | Unknown | iCell Gene Therapeutics | 12 | 2018-08-31 | 2019-11-12 |
| CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies CD20-CD19 cCAR T cells - B Cell Lymphoma, B Cell Leukemia | Early Phase 1 | Unknown | iCell Gene Therapeutics | 12 | 2018-08-01 | 2019-11-12 |
| CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies CD123-CD33 cCAR T cells - Hematologic Malignancy, Acute Myeloid Leukemia | Early Phase 1 | Unknown | iCell Gene Therapeutics | 20 | 2018-03-01 | 2019-11-12 |
| CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies CLL1-CD33 cCAR T cells - Hematologic Malignancy, Acute Myeloid Leukemia | Early Phase 1 | Unknown | iCell Gene Therapeutics | 20 | 2018-03-01 | 2021-05-19 |
| CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies CD19 CARvac T cells - B Cell Lymphoma, B Cell Leukemia | Early Phase 1 | Unknown | iCell Gene Therapeutics | 20 | 2018-02-01 | 2019-11-12 |
Leukemia (7) · Leukemia, Myeloid, Acute (5) · Lymphoma (5) · Hematologic Neoplasms (4) · Lymphoma, T-Cell (4) · Leukemia, T-Cell (3) · Recurrence (3) · Autoimmune Diseases (2) · Leukemia, B-Cell (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Lupus Erythematosus, Systemic (2) · Lymphoma, B-Cell (2) · Multiple Myeloma (2) · Myelodysplastic Syndromes (2) · Myeloproliferative Disorders (2)
Cyclophosphamide (1)
China (16) · United States (4)
Fang Liu, MD, PhD (5) · Hongyu Zhang, MD, PhD (5) · Hongyu Zhang, MD/PhD (3) · Fang Liu, MD/PhD (2) · Peihua Lu, MD (2) · Hongyu Zhang (1) · Huda Salman, MD (1) · Huda Salman, MD, PhD (1) · Jennifer Schwartz, MD (1)